Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.
February 12, 2021
Requiring passengers to return negative COVID-19 tests as a condition to travel unfairly signals out the airline industry and would add exceedingly little benefit compared to the costs it would impose.
January 28, 2021
We now have a new capability for vaccine design and manufacturing that is essentially modular, because we can now package an essentially infinite variety of mRNAs into liposomes—a delivery system as generic as a UPS truck.
November 7, 2020
The president-elect’s overall approach to technology and innovation policy appears to be formulated to engage the government as an active partner alongside industry in spurring innovation—but also as a tougher regulator of many tech industries and technologies.
October 26, 2020
America leads in biopharmaceutical innovation and drug development, in large part due to effective life-science policies, including significant federal investment in basic research, robust in
October 2, 2020
Gene editing’s enormous promise for solving societal problems, including climate change, has been slowed by concerns that it is neither natural nor safe.
September 15, 2020
Stephen Ezell gave a presentation about the federal policies needed to turbocharge America’s biomanufacturing renaissance at the AURP BioHealth Caucus Conference on September 15, 2020.
September 8, 2020
China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
August 13, 2020
Five Reasons State Attorneys General Are Misguided in Their Call to Apply March-In Rights on Remdesivir
Thirty-two state attorneys general have called for applying Bayh-Dole march-in rights on the only widely available therapeutic that has been FDA-approved for emergency use in treating coronavirus. They are wrong on both the facts and the law. As worryingly, their move threatens to undermine an effective environment for U.S. life-sciences innovation.
July 16, 2020
If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy.
July 16, 2020
Marking the release of a new report, ITIF hosted a discussion with experts and leaders from leading biopharmaceutical startups to discuss current challenges and opportunities, and what the federal government should and should not do to maintain this unique American strength.